---
title: "Taltz (ixekizumab), all indications: Safety questions"
description: "Safety questions on Taltz (ixekizumab) that apply to every indication, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Administration reactions, Infection precautions, Warnings, and Vaccines. Questions: Does Taltz Citrate-Free cause less injection site pain than the original formulation? Does Taltz require TB testing before treatment? Can Taltz cause eczema? Can Taltz cause allergic reactions? 5 further questions follow. 9 questions quoted from 3 sources."
canonical: "https://www.evicenter.com/medical-information/taltz/safety"
published: "2026-11-14T01:54:55-05:00"
modified: "2026-11-14T16:49:54-05:00"
---

# Taltz (ixekizumab), all indications: Safety questions

Manufacturer: Eli Lilly and Company  
Prescribing information: [Taltz](https://uspl.lilly.com/taltz/taltz.html#pi)  
Indication pages: [Plaque psoriasis](https://www.evicenter.com/medical-information/taltz--plaque-psoriasis)

## Administration reactions

<a id="taltz-citrate-free"></a>

### Does Taltz Citrate-Free cause less injection site pain than the original formulation?

> “Taltz Citrate-Free: The same active ingredient with significantly less injection site pain vs the original formulation<sup>1*</sup>
> <sup>*</sup>P<.0001; 3.5 vs 25.2 based on VAS 0-100”

Source: [TALTZ: Plaque Psoriasis (PsO) Dosing Schedule & Devices, captured 2026-11-14](https://taltz.lilly.com/hcp/dermatology/dosing-schedule#:~:text=Taltz%20Citrate%2DFree%3A%20The%20same%20active,25.2%20based%20on%20VAS%200%2D100)

> “Using Taltz Citrate-Free, people reported significantly less pain immediately after injection<sup>4*</sup>”

Source: [TALTZ: Plaque Psoriasis (PsO) Dosing Schedule & Devices, captured 2026-11-14](https://taltz.lilly.com/hcp/dermatology/dosing-schedule#:~:text=Using%20Taltz%20Citrate%2DFree%2C%20people%20reported%20significantly%20less%20pain%20immediately%20after)

> “<sup>*</sup>*P<.0001 vs Taltz original formulation; based on VAS 0-100”

Source: [TALTZ: Plaque Psoriasis (PsO) Dosing Schedule & Devices, captured 2026-11-14](https://taltz.lilly.com/hcp/dermatology/dosing-schedule#:~:text=vs%20Taltz%20original%20formulation%3B%20based%20on%20VAS%200%2D100)

> “VAS=visual analog scale; LSM=least squares mean.”

Source: [TALTZ: Plaque Psoriasis (PsO) Dosing Schedule & Devices, captured 2026-11-14](https://taltz.lilly.com/hcp/dermatology/dosing-schedule#:~:text=VAS%3Dvisual%20analog%20scale%3B%20LSM%3Dleast%20squares%20mean.)

> “Chabra S, Gill BJ, Gallo G, et al. Ixekizumab citrate-free formulation: results from two clinical trials. Adv Ther. 2022;Epub (Incl Suppl Inf):1-11, 1-4.”

Source: [TALTZ: Plaque Psoriasis (PsO) Dosing Schedule & Devices, captured 2026-11-14](https://taltz.lilly.com/hcp/dermatology/dosing-schedule#:~:text=Chabra%20S%2C%20Gill%20BJ%2C%20Gallo,2022%3BEpub%20%28Incl%20Suppl%20Inf%29%3A1%2D11%2C%201%2D4.)

Note: The study population is described behind a "Taltz Citrate-Free Injection Pain Study Design" link on the Taltz HCP dosing page, whose text was not part of the capture. The last passage is the first entry of the dosing page's reference list.

## Infection precautions

<a id="taltz-tuberculosis"></a>

### Does Taltz require TB testing before treatment?

> “Evaluate patients for tuberculosis (TB) infection prior to initiating treatment with TALTZ. Do not administer to patients with active TB infection. Initiate treatment of latent TB prior to administering TALTZ. Consider anti-TB therapy prior to initiating TALTZ in patients with a past history of latent or active TB in whom an adequate course of treatment cannot be confirmed. Patients receiving TALTZ should be monitored closely for signs and symptoms of active TB during and after treatment.”

Source: [TALTZ: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/taltz/taltz.html#pi:~:text=Evaluate%20patients%20for%20tuberculosis%20%28TB%29%20infection%20prior,TB%20during%20and%20after%20treatment.)

## Warnings

<a id="taltz-eczema"></a>

### Can Taltz cause eczema?

> “In the postmarketing setting, cases of severe eczematous eruptions, including atopic dermatitis-like eruptions, dyshidrotic eczema, and erythroderma were reported in patients receiving TALTZ; some cases resulted in hospitalization. The onset of eczematous eruptions was variable, ranging from days to months after the first dose of TALTZ. Treatment may need to be discontinued to resolve the eczematous eruption. Some patients with limited psoriasis treatment options were successfully treated for eczema while continuing TALTZ.”

Source: [TALTZ: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/taltz/taltz.html#pi:~:text=In%20the%20postmarketing%20setting%2C%20cases%20of%20severe%20eczematous%20eruptions%2C,for%20eczema%20while%20continuing%20TALTZ.)

<a id="taltz-allergic-reactions"></a>

### Can Taltz cause allergic reactions?

> “Serious hypersensitivity reactions, including angioedema and urticaria (each ≤0.1%), occurred in the TALTZ group in clinical trials. Anaphylaxis, including cases leading to hospitalization, has been reported in post marketing use with TALTZ [see Adverse Reactions (6.1, 6.3)]. If a serious hypersensitivity reaction occurs, discontinue TALTZ immediately and initiate appropriate therapy.”

Source: [TALTZ: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/taltz/taltz.html#pi:~:text=Serious%20hypersensitivity%20reactions%2C%20including%20angioedema,immediately%20and%20initiate%20appropriate%20therapy.)

<a id="taltz-contraindications"></a>

### What are the contraindications for Taltz?

> “TALTZ is contraindicated in patients with a previous serious hypersensitivity reaction, such as anaphylaxis, to ixekizumab or to any of the excipients [see Warnings and Precautions (5.3)].”

Source: [TALTZ: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/taltz/taltz.html#pi:~:text=TALTZ%20is%20contraindicated%20in%20patients,%5Bsee%20Warnings%20and%20Precautions%20%285.3%29%5D.)

<a id="taltz-boxed-warning"></a>

### Does Taltz have a boxed warning?

> “NO BOXED WARNINGS OR ROUTINE LAB MONITORING REQUIRED<sup>4‡</sup>”

Source: [TALTZ: Efficacy, Safety & Head-to-Head Data in PsO, captured 2026-11-14](https://taltz.lilly.com/hcp/dermatology/adult-psoriasis#:~:text=NO%20BOXED%20WARNINGS%20OR%20ROUTINE%20LAB%20MONITORING)

> “<sup>‡</sup>During Taltz treatment, monitor patients for signs and symptoms of infection and for onset or exacerbation of inflammatory bowel disease. During and after treatment with Taltz, monitor patients for active tuberculosis (TB) infection.”

Source: [TALTZ: Efficacy, Safety & Head-to-Head Data in PsO, captured 2026-11-14](https://taltz.lilly.com/hcp/dermatology/adult-psoriasis#:~:text=Taltz%20treatment%2C%20monitor%20patients%20for%20signs,for%20active%20tuberculosis%20%28TB%29%20infection.)

<a id="taltz-suicidal-ideation"></a>

### Does the Taltz label warn about suicidal thoughts or behavior?

> “The Taltz label does not contain suicidal ideation and behavior as an adverse reaction or warning<sup>4</sup>”

Source: [TALTZ: Efficacy, Safety & Head-to-Head Data in PsO, captured 2026-11-14](https://taltz.lilly.com/hcp/dermatology/adult-psoriasis#:~:text=The%20Taltz%20label%20does%20not,as%20an%20adverse%20reaction%20or)

<a id="taltz-cancer-risk"></a>

### Does Taltz increase the risk of cancer?

> “Animal studies have not been conducted to evaluate the carcinogenic or mutagenic potential of TALTZ. Moreover published literature is mixed on potential effects on malignancy risk due to the inhibition of IL-17A activity, the pharmacological action of TALTZ. Some published literature suggests that IL-17A directly promotes cancer cell invasion, suggesting a potential beneficial effect by TALTZ, whereas other reports indicate IL-17A promotes T-cell mediated tumor rejection, suggesting a potential adverse effect by TALTZ. However, neutralization of IL-17A with TALTZ has not been studied in these models. Depletion of IL-17A with a neutralizing antibody inhibited tumor development in mice, suggesting a potential beneficial effect by TALTZ. The relevance of experimental findings in mouse models for malignancy risk in humans is unknown.”

Source: [TALTZ: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/taltz/taltz.html#pi:~:text=Animal%20studies%20have%20not%20been,risk%20in%20humans%20is%20unknown.)

> “Certain adverse events, such as malignancy, require longer observation periods and larger patient exposure to ascertain risk. In the reported safety population of the psoriasis clinical trials, not all patients received the recommended dosing regimen consistent with the FDA-approved label.”

Source: [TALTZ: Efficacy, Safety & Head-to-Head Data in PsO, captured 2026-11-14](https://taltz.lilly.com/hcp/dermatology/adult-psoriasis#:~:text=Certain%20adverse%20events%2C%20such%20as,consistent%20with%20the%20FDA%2Dapproved%20label.)

## Vaccines

<a id="taltz-live-vaccines"></a>

### Can patients on Taltz get live vaccines?

> “Prior to initiating therapy with TALTZ, consider completion of all age-appropriate immunizations according to current immunization guidelines. Avoid use of live vaccines in patients treated with TALTZ. No data are available on the response to live vaccines.”

Source: [TALTZ: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/taltz/taltz.html#pi:~:text=Prior%20to%20initiating%20therapy%20with,the%20response%20to%20live%20vaccines.)

## Related pages
- [Medical information: Taltz (ixekizumab): All indications](https://www.evicenter.com/medical-information/taltz)
- [Indication](https://www.evicenter.com/medical-information/taltz/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/taltz/pharmacology)
- [Specific populations](https://www.evicenter.com/medical-information/taltz/specific-populations)
- [Dosing and administration](https://www.evicenter.com/medical-information/taltz/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/taltz/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/taltz/access-and-coverage)
